Dr. David (Hyungul) Yang earned his degree in immunology from POSTECH, Korea. Drawing on his expertise, he has worked on DNA vaccine development, gene therapy research, and cell therapeutics utilizing genetically engineered mesenchymal stem cells and NK cells. Since joining Panolos Bioscience in 2019, Dr. Yang has been instrumental in the progression of PB101—an anti-angiogenic protein drug that not only suppresses abnormal angiogenesis but also enhances the anti-tumor immune response. He took charge of its toxicity evaluations and preclinical animal efficacy studies. In a significant step forward, the IND for PB101 gained approval this year. Presently, Dr. Yang is at the forefront of the development of PB203, an innovative immuno-oncologic multispecific protein drug.